The new class of GLP-1 glucagon drugs has, once again, shown that it can obliterate liver fat.
Fatty liver disease might be a thing of the past when these things hit the market.
Consider this earlier result for Retatrutide, where they saw 80% reductions in 24 weeks:
Now you see it now you donât đâ¨
Before and after survodutide 48 weeks treatment.
35% liver fat content âĄď¸ 2% fat content in this patient.
Poof đŞđ¨
Results from survodutideâs SYNCHRONIZE-MASLD trial.